ライフサイエンスコーパス: PPAR-alpha

1 ad been deleted by homologous recombination (PPAR-alpha(-/-)).

2 isome proliferator-activated receptor alpha (PPAR alpha).

3 isome proliferator-activated receptor alpha (PPAR alpha).

4 isome proliferator-activated receptor alpha (PPAR-alpha).

5 l M2 genes (IL-13, SPHK1, CD163, LYVE-1, and PPAR-alpha).

6 isome proliferator-activated receptor-alpha (PPAR-alpha).

7 some proliferators activated receptor-alpha (PPAR-alpha).

8 isome proliferator-activated receptor alpha (PPAR-alpha).

9 me peptides on PPAR delta and in one case on PPAR alpha.

10 iferation, but not in the genetic absence of PPAR alpha.

11 lta-subtype can compensate for deficiency of PPAR alpha.

12 e from a Th1 to a Th2 profile independent of PPAR-alpha.

13 sses the activity of PPAR-gamma (PPAR-g) and PPAR-alpha.

14 mice but has no effect in mice deficient in PPAR-alpha.

15 which also were dependent on the presence of PPAR-alpha.

16 e its analog OEA, as an endogenous ligand of PPAR-alpha.

17 re that, in the liver, TRB-3 is a target for PPAR-alpha.

18 wild-type mice, but not in mice deficient in PPAR-alpha.

19 re stimulated by pharmacologic activation of PPAR-alpha.

20 alpha, the dominant-negative mutant of human PPAR-alpha.

21 hat gemfibrozil inhibits iNOS independent of PPAR-alpha.

22 gonists and abolished in mutant mice lacking PPAR-alpha.

23 s the activation of microglia independent of PPAR-alpha.

24 cts of 15D-PGJ2 may include 1) activation of PPAR-alpha, 2) activation of PPAR-gamma, 3) expression o

25 isome proliferator-activated receptor alpha (PPAR alpha), a member of the nuclear receptor family.

26 isome proliferator-activated receptor alpha (PPAR-alpha), a fatty acid binding transcription factor t

27 isome-proliferator-activated receptor-alpha (PPAR-alpha), a nuclear receptor that regulates several a

28 creases the activity of the nuclear receptor PPAR-alpha, a PGC-1alpha binding partner, to promote fat

29 n insulin sensitivity, and direct effects of PPAR-alpha action on the islet itself.

30 is study demonstrates that the activation of PPAR-alpha action via fenofibrate leads to neuroprotecti

31 h LDL(-) alone, LPL-treated LDL(-) increased PPAR alpha activation 20-fold in either cell-based trans

32 These findings suggest LPL-mediated PPAR alpha activation as an alternative catabolic pathwa

33 Although human plasma possesses minimal PPAR alpha activation despite containing abundant free f

34 containing abundant free fatty acids, marked PPAR alpha activation is seen with human plasma after LP

35 The PPAR alpha activation seen with LDL, however, was dispro

36 These findings suggest PPAR-alpha activation as a hepatoprotective adaptive res

37 e insulin secretory response to lipid and of PPAR-alpha activation in the cause of fasting hyperinsul

38 PPAR-alpha activation in the enterocyte on HDL and chylo

39 PPAR-alpha activation in vivo led to increased insulin s

40 lipids, the pharmacological consequences of PPAR-alpha activation on cardiac metabolism and function

41 expressed genes between PPAR-beta/delta and PPAR-alpha activation revealed distinct profiles.

42 Previous studies have demonstrated that PPAR-alpha activation stimulates keratinocyte differenti

43 In contrast to PPAR-alpha activation, PPAR-beta/deltain vivo did not di

44 nd anti-inflammatory effects exerted through PPAR-alpha activation.

45 AR-gamma activator (troglitazone), but not a PPAR-alpha activator (bezafibrate), strikingly diminishe

46 de that LTB(4) is a physiologically relevant PPAR-alpha activator in cells of the immune system.

47 ydroxy-octadecadienoic acids (HODEs), potent PPAR alpha activators.

48 de an added benefit to patients treated with PPAR-alpha activators for dyslipidemia.

49 PPAR-alpha activators, including fibrates, have been use

50 of fibroblasts with ciprofibrate or WY14643, PPAR-alpha activators, led to peroxisome proliferation a

51 Importantly, both PPAR-alpha activators, such as the fibric acid class of

52 oducts as candidate physiologically relevant PPAR-alpha activators.

53 on of antisteatotic versus anti-inflammatory PPAR-alpha activities in counteracting dietary-induced l

54 sion, and this suggests that ATGL influences PPAR-alpha activity independently of ligand-induced acti

55 In fact, PPAR-alpha agonism overstimulated mitochondrial TCA cycl

56 However, PPAR-alpha agonism was unable to normalize the effects o

57 which were presumably due to the concomitant PPAR-alpha agonism, lower respiratory quotient, and less

58 s that were similar to those elicited by the PPAR alpha agonist GW647.

59 mRNA levels did not increase in response to PPAR alpha agonist treatment in the PPAR alpha-overexpre

60 This novel effect of the PPAR-alpha agonist could provide an added benefit to pat

61 weeks of either placebo (PLA) or 5 mg/kg of PPAR-alpha agonist fenofibrate (FEN) treatment, within 3

62 The PPAR-alpha agonist fenofibrate exhibited submicromolar a

63 Treatment of diabetic rats with a PPAR-alpha agonist induced hepatic fat oxidation via ket

64 The natural PPAR-alpha agonist oleoylethanolamide (OEA) and the synt

65 The synthetic PPAR-alpha agonist Wy-14643 produced similar effects, wh

66 patocytes treated with dexamethasone and the PPAR-alpha agonist Wy14,643 induced PPARA and gluconeoge

67 We further demonstrate that treatment with a PPAR-alpha agonist, bezafibrate, is able to reverse the

68 The results indicate that OEA, acting as a PPAR-alpha agonist, facilitates memory consolidation thr

69 y studying the effects of a highly selective PPAR-alpha agonist, GW7647, on [(14)C]oleate metabolism

70 A highly selective and potent PPAR-alpha agonist, GW7647, was administered by mouth fo

71 amine the safety and efficacy of LY518674, a PPAR-alpha agonist.

72 isome proliferator-activated receptor-alpha (PPAR-alpha) agonist WY-14,643 and the glucocorticoid dex

73 the present study, we demonstrate that these PPAR alpha agonists can increase the production of the T

74 ne protein-70 (PMP-70) were not regulated by PPAR alpha agonists in human hepatocytes.

75 These results suggest that PPAR alpha agonists such as gemfibrozil and fenofibrate,

76 The PPAR alpha agonists, gemfibrozil, ciprofibrate, and feno

77 CPT-1) were also regulated in HepG2 cells by PPAR alpha agonists.

78 The actions of OEA are mimicked by PPAR-alpha agonists and abolished in mutant mice lacking

79 Next generation PPAR-alpha agonists are more potent at high-density lipo

80 stress was evident in mice treated with the PPAR-alpha agonists coinciding with increased peroxisoma

81 drazine (PHZ)-induced stress erythropoiesis, PPAR-alpha agonists facilitate recovery of wild-type but

82 activated receptor alpha (PPAR-alpha) by the PPAR-alpha agonists GW7647 and fenofibrate synergizes wi

83 t oleoylethanolamide (OEA) and the synthetic PPAR-alpha agonists GW7647 and Wy-14643 mimic these effe

84 Two distinct PPAR-alpha agonists have similar effects that are also c

85 Our discovery of the role of PPAR-alpha agonists in stimulating self-renewal of early

86 ly explain the sometimes equivocal effect of PPAR-alpha agonists on glycemia.

87 or cells suggests that the clinically tested PPAR-alpha agonists we used may improve the efficacy of

88 y chromatin sites with GR; when activated by PPAR-alpha agonists, additional PPAR-alpha is recruited

89 Dissociated PPAR-alpha agonists, selectively modulating PPAR-alpha t

90 We also show that PPAR-alpha alleviates anaemia in a mouse model of chroni

91 Interestingly, although PPAR alpha also exhibited high affinity for saturated lo

92 hat human airway smooth muscle cells express PPAR alpha and -gamma subtypes.

93 It interacts with PPAR alpha and acts as a coactivator by moderately stimu

94 PPAR delta agonist activity, improvement of PPAR alpha and gamma activity required the introduction

95 athways points to the critical importance of PPAR alpha and of the classical peroxisomal fatty acyl-C

96 ha, although only in the genetic presence of PPAR alpha and with intact LPL hydrolysis.

97 Palmitoylethanolamide is an agonist of PPAR-alpha and an important regulator of pain and innate

98 ion downregulated mRNA expression of cardiac PPAR-alpha and FAO enzyme genes, decreased myocardial FA

99 ing effects, and safety profile, of the dual PPAR-alpha and PPAR-gamma agonist aleglitazar.

100 review highlights the emerging evidence for PPAR-alpha and PPAR-gamma expression in the vasculature,

101 eNOS transgenic mice showed higher levels of PPAR-alpha and PPAR-gamma gene expression, elevated abun

102 ulates fat utilization through activation of PPAR-alpha and that this effect may contribute to its an

103 ss of fat, we infused adenovirus-leptin into PPAR alpha(-/-) and PPAR alpha(+/+) mice.

104 PPAR ligands such as fibrates (PPAR-alpha) and insulin-sensitizing thiazolidinediones (

105 isome proliferator-activated receptor alpha (PPAR-alpha) and its target genes in mice with suppressed

106 isome proliferator-activated receptor-alpha (PPAR-alpha), and liver X receptor-alpha (LXRalpha).

107 three nuclear receptor isoforms, PPAR gamma, PPAR alpha, and PPAR delta, encoded by different genes.

108 diated through AMP-activated protein kinase, PPAR-alpha, and PPAR-gamma coactivator alpha, which in t

109 the DNA-binding activities of HNF-4alpha and PPAR-alpha, and reduced HNF-4alpha and PPAR-alpha target

110 c(+) ATMPhis expressing elevated PGC-1alpha, PPAR-alpha, and Ym-1 transcripts were selectively enrich

111 diet-induced hepatic insulin resistance in a PPAR-alpha-and diacylglycerol-dependent manner.

112 cell carcinoma, and support the concept that PPAR-alpha antagonism may be a potential therapeutic app

113 g-induced reinstatement were reversed by the PPAR-alpha antagonist, MK886.

114 uorescence resonance energy transfer between PPAR alpha aromatic amino acids and bound corresponding

115 These results identify hepatic activation of PPAR-alpha as a mechanism underlying glucocorticoid-indu

116 opment of therapeutic strategies to activate PPAR-alpha as well as other PPARs may lead to new therap

117 (Tricor), a pan-PPAR agonist that activates PPAR-alpha as well as other PPARs.

118 isome proliferator-activated receptor-alpha (PPAR-alpha) as the molecular target responsible for the

119 peroxisome proliferator-activated receptor (PPAR alpha) binds and is activated by a variety of synth

120 eroxyeicosatetrenoic acid (5-HPETE) activate PPAR-alpha but have no significant endogenous effect ind

121 rentiating effects persisted in mice lacking PPAR-alpha, but were decreased in mice deficient in reti

122 teatosis, and reactivation of HNF-4alpha and PPAR-alpha by increasing zinc availability and inhibitin

123 isome proliferator-activated receptor alpha (PPAR-alpha) by the PPAR-alpha agonists GW7647 and fenofi

124 trol and corticosteroid-treated BFU-E cells, PPAR-alpha co-occupies many chromatin sites with GR; whe

125 known how putative endogenous ligands alter PPAR alpha conformation in order to affect transcription

126 tissue repair in WT-DB mice, but not in the PPAR-alpha-/--DB mice.

127 re absent in endothelial cells isolated from PPAR alpha-deficient mice.

128 idized EPA had no such effect in LPS-treated PPAR alpha-deficient mice.

129 Studies in PPAR-alpha-deficient mice demonstrated that cardiomyocyt

130 No such effect was seen in PPAR-alpha-deficient mice.

131 mimicked by exogenous PEA, and abolished by PPAR-alpha deletion.

132 Peroxisome proliferator-activated receptors (PPAR alpha, delta, gamma) are nuclear transcription fact

133 Three subfamilies, including PPAR-alpha, -delta, and -gamma, have been identified wit

134 The dual PPAR-alpha/delta agonist, GFT505, is a promising liver-t

135 proliferator-activated receptor alpha/delta (PPAR-alpha/delta) agonist.

136 This occurred via a PPAR alpha-dependent mechanism because oxidized EPA had

137 its protective effects are mediated by both PPAR-alpha-dependent and -independent mechanisms.

138 GW7647 and Wy-14643 mimic these effects in a PPAR-alpha-dependent manner.

139 By co-activating normal PPAR-alpha-dependent metabolism and abnormal PPAR-gamma

140 cement assays showed for the first time that PPAR alpha exhibits high affinity (1-14 nM K(d) values)

141 rovide unique insight into the regulation of PPAR-alpha expression and, importantly, provide an examp

142 Indeed, whereas PPAR-alpha expression is first noted at gestational day

143 Thus, although no changes in islet PPAR-alpha expression were observed after the starvation

144 similar effects that are also contingent on PPAR-alpha expression, whereas potent and selective agon

145 isome proliferator-activated receptor-alpha (PPAR-alpha) expression, but its function in this tissue

146 In contrast to the similar affinities of PPAR alpha for fatty acyl-CoAs and unsaturated fatty aci

147 nd develop the hypothesis that modulation of PPAR-alpha function may be important for the regulation

148 caused by dietary treatment with a PPAR-pan (PPAR-alpha, -gamma, and -delta) agonist were profiled by

149 s been identified as a non-thiazolidinedione PPAR alpha/gamma dual agonist that shows potent activity

150 f 4-thiazolyl-phenyl derivatives with potent PPAR alpha/gamma/delta pan agonistic activity.

151 Subsequent studies revealed that the PPAR-alpha gene bears a DNA consensus motif for the tran

152 substrate (VLDL >> LDL > HDL), PPAR isoform (PPAR alpha >> PPAR delta > PPAR gamma), and among fatty

153 igand binding domain activation in the order PPAR-alpha> >-gamma>-delta.

154 and wild-type mice, but not in mice in which PPAR-alpha had been deleted by homologous recombination

155 in nonhepatoma cells, whereas the RXR alpha-PPAR alpha heterodimer inhibits HNF4-dependent DHBV repl

156 isome proliferator-activated receptor alpha (PPAR alpha) heterodimer without greatly altering the eff

157 isome proliferator-activated receptor alpha (PPAR alpha) heterodimer.

158 n nonhepatoma cells indicates that RXR alpha-PPAR alpha heterodimers support higher levels of pregeno

159 show that OEA induces satiety by activating PPAR-alpha, identify an unexpected role for this nuclear

160 ing or intracellular lipids by activation of PPAR-alpha improved insulin sensitivity and the diabetic

161 ear extracts that interacts with full-length PPAR alpha in the presence of ciprofibrate, a synthetic

162 ically distinct activators of PPAR-gamma and PPAR-alpha in a rat model of acute myocardial infarction

163 sion of wild-type or a DNA-binding-deficient PPAR-alpha in acute and chronic models of inflammation w

164 The role of PPAR-alpha in acute ischemia/reperfusion myocardial inju

165 APAP toxicity, suggesting the importance of PPAR-alpha in diabetes-induced protection.

166 alpha (PPAR-alpha), we were unable to detect PPAR-alpha in either gemfibrozil-treated or untreated hu

167 uced both PPRE binding and nuclear levels of PPAR-alpha in fatty livers but increased those in lean l

168 but not isoform 2) as well as PPAR-beta and PPAR-alpha in freshly isolated cardiac myocytes and card

169 ha (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS.

170 The results suggest that PEA activation of PPAR-alpha in leukocytes serves as an early stop signal

171 Adenoviral reconstitution of PPAR-alpha in the livers of nondiabetic, normotensive, d

172 PEA selectively activates PPAR-alpha in vitro with an EC(50) value of 3.1 +/- 0.4

173 after the starvation protocol, activation of PPAR-alpha in vivo may be a potential mechanism underlyi

174 isome proliferator-activated receptor-alpha (PPAR-alpha) in microglial cells and isolating primary mi

175 peroxisome proliferator-activated receptors (PPAR-alpha) in the gut and recruiting local afferents of

176 isome proliferator-activated receptor-alpha (PPAR-alpha), in inhibiting the disease process of adopti

177 We demonstrate that two distinct ligands of PPAR-alpha (including clofibrate and WY 14643) also caus

178 ect the expression of genes independently of PPAR alpha, including the gene for the major inducible d

179 To determine the role of PPAR-alpha-independent mechanisms, the effect of GFT505

180 d inflammation, indicating a contribution of PPAR-alpha-independent mechanisms.

181 llar bilayers was delayed in animals lacking PPAR-alpha, indicating a transient functional defect.

182 activity and units indicates that clofibrate/PPAR alpha induced expression of retinal-reducing enzyme

183 Pharmacologically activated PPAR-alpha inhibited hepatic inflammatory responses and

184 ification of such a transcriptionally active PPAR alpha-interacting cofactor (PRIC) complex from rat

185 Activation of PPAR-alpha is a direct effect of intracellularly generat

186 activated by PPAR-alpha agonists, additional PPAR-alpha is recruited to GR-adjacent sites and presuma

187 isome proliferator-activated receptor alpha (PPAR-alpha) is a potential candidate for this key regula

188 isome proliferator-activated receptor-alpha (PPAR-alpha) is expressed in the heart and regulates gene

189 In the present study we used PPAR alpha knockout (KO) mice to determine whether this

190 ct of GFT505 was assessed in hApoE2 knock-in/PPAR-alpha knockout mice.

191 These findings suggest that activation of PPAR-alpha leads to increased cardiac fatty acid oxidati

192 e results suggest that other factors besides PPAR alpha levels determine the species-specific respons

193 a diet containing clofibrate (0.5%, w/w), a PPAR alpha ligand and peroxisome proliferator, increased

194 The PPAR-alpha ligand pirinixic acid (WY14643) functionally

195 on of PPAR-alpha receptors using a selective PPAR-alpha ligand results in cardiomyocyte necrosis in m

196 somal proliferator-activated receptor alpha (PPAR alpha) ligand, thus limiting inflammation.

197 We found that PPAR alpha ligands (clofibrate and WY14643) enhanced IL-

198 Moreover, other genes that are regulated by PPAR alpha ligands in human hepatocytes such as mitochon

199 han saturated fatty acids, are high affinity PPAR alpha ligands provides a mechanism accounting for s

200 act on circulating lipoproteins to generate PPAR alpha ligands, providing a potentially important li

201 ed fatty acids may both represent endogenous PPAR alpha ligands.

202 ifferent types of lipids serve as endogenous PPAR-alpha ligands, with the relevant ligand varying bet

203 derived from ATGL-catalyzed lipolysis act as PPAR-alpha ligands.

204 We have attempted to analyze the role of PPAR-alpha-linked fatty acid metabolism in islet functio

205 We speculate that ligands of PPAR-gamma and PPAR-alpha may be useful in the therapy of conditions as

206 cate that HIF-1-dependent down-regulation of PPAR-alpha may provide an adaptive response to proinflam

207 eptor (PPAR) gamma coactivator-1 (PGC-1) and PPAR-alpha may shift myocytes toward glycolytic metaboli

208 iptional activation of lipogenesis, FXR-RXR, PPAR-alpha mediated lipid oxidation and oxidative stress

209 of omega-3 fatty acids may be explained by a PPAR alpha-mediated anti-inflammatory effect of oxidized

210 s as a coactivator by moderately stimulating PPAR alpha-mediated transcription in transfected cells.

211 inhibitor of beta-oxidation, indicating that PPAR-alpha-mediated TAG depletion does not depend on rec

212 These findings indicate that PPAR-alpha mediates the anti-inflammatory effects of PEA

213 isome proliferator-activated receptor-alpha (PPAR-alpha) mediates these sequelae, mice deficient in l

214 hogenesis of cardiac dysfunction by crossing PPAR-alpha mice with transgenic mice with cardiac-specif

215 tion in skeletal muscle strips isolated from PPAR-alpha mice.

216 d adenovirus-leptin into PPAR alpha(-/-) and PPAR alpha(+/+) mice.

217 Thus, in PPAR alpha(-/-) mice, up-regulation of carnitine palmito

218 reduced in the liver of wild-type but not in PPAR alpha(-/-) mice.

219 liver of wild-type mice but was unchanged in PPAR alpha(-/-) mice.

220 n the wild-type mice but did not increase in PPAR alpha(-/-) mice.

221 ght declined 55% in wild-type but only 6% in PPAR alpha(-/-) mice; liver triacylglycerol fell 39% in

222 se rats and wild-type mice, but not in obese PPAR-alpha(-/-) mice.

223 dendrocytes isolated from both wild type and PPAR-alpha(-/-) mice.

224 In PPAR-alpha-/- mice we observed delayed stratum corneum f

225 l cells and isolating primary microglia from PPAR-alpha-/- mice, we have demonstrated that gemfibrozi

226 liferation and cell death appeared normal in PPAR-alpha-/- mice.

227 rformed on livers from non-DB and DB (WT and PPAR-alpha-/-) mice at 0 and 12 h after APAP.

228 In contrast, diabetes in PPAR knockout (PPAR-alpha-/-) mice failed to protect against APAP toxic

229 y pretreatment with an antagonist for either PPAR-alpha (MK886) or cannabinoid CB1 receptors (rimonab

230 revealed that hypoxia rapidly down-regulates PPAR-alpha mRNA and protein in epithelial cells in vitro

231 +/- 0.4 microM and induces the expression of PPAR-alpha mRNA when applied topically to mouse skin.

232 ng dietary-induced liver fibrosis, we used a PPAR-alpha mutant lacking its DNA-binding-dependent acti

233 al structure of the ligand binding domain of PPAR alpha (NR1C1) as a complex with the agonist ligand

234 To directly test this hypothesis, we fed PPAR-alpha null and wild-type mice for 2 weeks with isoc

235 fed safflower oil), whereas in contrast, in PPAR-alpha null mice failed to counteract hepatic insuli

236 In PPAR-alpha null mice fed the fish oil diet, safflower oi

237 hepatic insulin resistance (HGP, P = NS vs. PPAR-alpha null safflower oil-fed mice).

238 In the small intestine of wild-type but not PPAR-alpha-null mice, OEA regulates the expression of se

239 ection by GW7647 was completely abolished in PPAR-alpha-null mice.

240 The transrepression activity of PPAR-alpha on chronic liver inflammation is sufficient t

241 emphasized the potential for both actions of PPAR-alpha on insulin sensitivity that may be relayed sy

242 lta is severalfold more abundant than either PPAR alpha or PPAR gamma.

243 These PPAR alpha-overexpressing cells had higher basal mRNA le

244 ponse to PPAR alpha agonist treatment in the PPAR alpha-overexpressing cells, although mitochondrial

245 athic phenotype that occurred as a result of PPAR-alpha overexpression without affecting the metaboli

246 Evidence derived from mice deficient in PPAR alpha, peroxisomal fatty acyl-CoA oxidase, and some

247 ight gain by activating the nuclear receptor PPAR-alpha (peroxisome proliferator-activated receptor a

248 These data relate retinoid metabolism, PPAR alpha, peroxisomes, and RRD, and are consistent wit

249 These results indicate that PPAR-alpha plays a physiologic role during fetal stratum

250 This study was designed to test whether PPAR-alpha plays a physiologic role in epidermal differe

251 isome proliferator-activated receptor alpha (PPAR alpha) plays a central role in the cell-specific pl

252 ave a subfamily of three different isoforms: PPAR alpha, PPAR gamma, and PPAR beta/delta.

253 ome proliferator-activated receptors (PPARs; PPAR-alpha, PPAR-delta, and PPAR-gamma) comprise a famil

254 peroxisome proliferator-activated receptors (PPAR-alpha, PPAR-gamma and PPAR-delta) exemplify this co

255 FAS, PPAR-alpha, PPAR-gamma, and CB1-R were markedly altered

256 Treatments that activate PPAR-alpha, PPAR-gamma, and PPAR-delta alone or in combi

257 me proliferator-activated receptors (PPARs), PPAR-alpha, PPAR-gamma, and PPAR-delta.

258 than currently available fibrates, and dual PPAR-alpha/PPAR-gamma agonists are under investigation t

259 The liganded PPAR alpha-PRIC complex enhanced transcription from a pe

260 Activation of PPAR-alpha protected the heart from reperfusion injury.

261 Robust induction of PPAR-alpha protein expression occurred during muscle cel

262 ntrast, hepatic levels of the PPAR-gamma and PPAR-alpha proteins were significantly lower in the Acc2

263 In contrast, activators of PPAR-alpha, RAR, RXR, or vitamin D receptor did not alte

264 Therefore, we evaluated the role that PPAR-alpha receptors play in the heart.

265 Our studies demonstrate that activation of PPAR-alpha receptors using a selective PPAR-alpha ligand

266 crosis is a consequence of the activation of PPAR-alpha receptors.

267 lpha-type peroxisome proliferator-activated (PPAR-alpha) receptors; (2) shifted nicotine self-adminis

268 We conclude that liganded PPAR alpha recruits a distinctive multiprotein complex f

269 Activation of PPAR-alpha reduces secretion of LTB(4) by stimulating de

270 Fasting increased expression of all PPAR-alpha -regulated genes in lean Zucker rat hearts, w

271 During fasting, a microbiota-dependent, Ppar alpha-regulated increase in hepatic ketogenesis occ

272 with the nuclear hormone receptors HNF-4 and PPAR-alpha, respectively.

273 fier of PGC-1alpha, a nuclear coactivator of PPAR-alpha responsive gene transcription.

274 ic models of inflammation were used to study PPAR-alpha's anti-inflammatory versus metabolic activiti

275 tion that 5-lipoxygenase stimulation induces PPAR-alpha signaling and that this results specifically

276 This miR-27b-mediated repression of PPAR-alpha signaling represents a novel mechanism of HCV

277 de an alternate mechanism that links ATGL to PPAR-alpha signaling.

278 isome proliferator-activated receptor alpha (PPAR-alpha) stimulation.

279 y acids), elicited conformational changes in PPAR alpha structure, a hallmark of ligand-activated nuc

280 P-1 activation, increasing expression of the PPAR alpha target gene I kappa B alpha, although only in

281 ein 3, two classical and robustly responsive PPAR alpha target genes, were similar between WT and KO

282 pe controls, despite comparable induction of PPAR alpha target genes.

283 r homogenates; and hepatic expression of key PPAR-alpha target (MCAD, mitochondrial HMG CoA synthase,

284 naling on SIRT1 activity, and PGC-1alpha and PPAR-alpha target gene expression independent of changes

285 o normalize the effects of ATGL knockdown on PPAR-alpha target gene expression, and this suggests tha

286 is required for the induction of PGC-1alpha/PPAR-alpha target genes and oxidative metabolism in resp

287 ice, OEA regulates the expression of several PPAR-alpha target genes: it initiates the transcription

288 a and PPAR-alpha, and reduced HNF-4alpha and PPAR-alpha target proteins.

289 Fatty acids bind and activate PPAR-alpha; therefore, it has been presumed that fatty a

290 We show here that MUT LDL activates PPAR alpha to an extent proportional to its LDL(-) conte

291 es were established that overexpressed human PPAR alpha to levels between 6- and 26-fold over normal

292 nk between lipoprotein metabolism and distal PPAR alpha transcriptional effects.

293 PPAR-alpha transgenic mice develop spontaneous cardiac h

294 PPAR-alpha agonists, selectively modulating PPAR-alpha transrepression activity, could thus be an op

295 PPAR-alpha was investigated further by immunohistochemis

296 isome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in g

297 isome proliferator-activated receptor-alpha (PPAR-alpha), we were unable to detect PPAR-alpha in eith

298 isome proliferator-activated receptor-alpha (PPAR-alpha) were examined as a model of diabetic cardiom

299 r-/-), with (Ppara+/+) or without (Ppara-/-) PPAR-alpha, were treated chronically with dexamethasone.

300 rug was equally effective in treating EAE in PPAR-alpha wild-type as well as knockout mice.